{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T07:18:12Z","timestamp":1778397492533,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.healun.2016.08.022","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T14:26:46Z","timestamp":1473863206000},"page":"355-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients"],"prefix":"10.1016","volume":"36","author":[{"given":"Johannes J.","family":"Kovarik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Kaltenecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Werzowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hecking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Mahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Gr\u00f6mmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Aumayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Kain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Zuckermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2016.08.022_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00041552-200401000-00015","article-title":"Why are angiotensin concentrations so high in the kidney?","volume":"13","author":"Navar","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.healun.2016.08.022_bib2","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.healun.2016.08.022_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.healun.2016.08.022_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2012.196","article-title":"Targeting the renin-angiotensin-aldosterone system in heart failure","volume":"10","author":"Lang","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.healun.2016.08.022_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2016.08.022_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2016.08.022_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2007.11.026","article-title":"Highlights of the 2007 scientific meeting of the Heart Failure Society of America: Washington, DC, September 16-19, 2007","volume":"51","author":"Mehra","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2016.08.022_bib8","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1681\/ASN.2006050543","article-title":"No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report","volume":"17","author":"Opelz","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.healun.2016.08.022_bib9","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1161\/01.CIR.0000075957.16003.07","article-title":"Cardiology patient page. What is an angiotensin converting enzyme inhibitor?","volume":"108","author":"Sweitzer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2016.08.022_bib10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade","volume":"4","author":"Biollaz","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.healun.2016.08.022_bib11","doi-asserted-by":"crossref","first-page":"F35","DOI":"10.1152\/ajprenal.00641.2009","article-title":"Chymase: the other ACE?","volume":"298","author":"Lorenz","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.healun.2016.08.022_bib12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJMe0908183","article-title":"Blood-pressure control and delay in progression of kidney disease in children","volume":"361","author":"Ingelfinger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2016.08.022_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.healun.2016.08.022_bib14","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1016\/j.transproceed.2005.10.099","article-title":"The effects of ACE inhibition on serum angiotensin II concentration following cardiac transplantation","volume":"37","author":"Fildes","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2016.08.022_bib15","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart","volume":"265","author":"Urata","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.healun.2016.08.022_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.crd.0000195220.62533.c5","article-title":"Chymase: a new pharmacologic target in cardiovascular disease","volume":"14","author":"Bacani","year":"2006","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.healun.2016.08.022_bib17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI39345","article-title":"Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents","volume":"120","author":"Wei","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.healun.2016.08.022_bib18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1172\/JCI42644","article-title":"The one-two punch: knocking out angiotensin II in the heart","volume":"120","author":"Zablocki","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.healun.2016.08.022_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1042\/CS20120111","article-title":"Angiotensin-(1\u20137) in kidney disease: a review of the controversies","volume":"123","author":"Zimmerman","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.healun.2016.08.022_bib20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.healun.2016.08.022_bib21","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1\u20137) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.healun.2016.08.022_bib22","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1\u20137) and Mas: new players of the renin-angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1016\/j.healun.2016.08.022_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.healun.2016.08.022_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","article-title":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1\u20137) in essential hypertension","volume":"14","author":"Luque","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.healun.2016.08.022_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fendo.2013.00201","article-title":"Update on the Angiotensin converting enzyme 2-Angiotensin (1\u20137)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways","volume":"4","author":"Chappell","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.healun.2016.08.022_bib26","first-page":"402","article-title":"Molecular changes of the angiotensin converting enzyme 2 pathway in myocardial tissue from heart failure patients undergoing heart transplantation","volume":"173","author":"Batlle","year":"2014","journal-title":"J Clin Exp Cardiolog"},{"key":"10.1016\/j.healun.2016.08.022_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.healun.2016.08.022_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ndt\/gfu265","article-title":"Molecular regulation of the renin-angiotensin system in haemodialysis patients","volume":"30","author":"Kovarik","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl I","key":"10.1016\/j.healun.2016.08.022_bib29","first-page":"177","article-title":"Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase","volume":"14","author":"Urata","year":"1993","journal-title":"Eur Heart J"},{"key":"10.1016\/j.healun.2016.08.022_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","article-title":"Angiotensin II-forming pathways in normal and failing human hearts","volume":"66","author":"Urata","year":"1990","journal-title":"Circ Res"},{"issue":"Suppl D","key":"10.1016\/j.healun.2016.08.022_bib31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurheartj\/15.suppl_D.68","article-title":"Tissue angiotensin II system in the human heart","volume":"15","author":"Urata","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.healun.2016.08.022_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.healun.2006.04.012","article-title":"Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure","volume":"25","author":"Batlle","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.08.022_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10557-013-6450-4","article-title":"Chymase inhibition and cardiovascular protection","volume":"27","author":"Tojo","year":"2013","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.healun.2016.08.022_bib34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cardiores.2003.11.029","article-title":"Vascular chymase: pathophysiological role and therapeutic potential of inhibition","volume":"61","author":"Doggrell","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.healun.2016.08.022_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease","volume":"59","author":"Kobori","year":"2007","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.healun.2016.08.022_bib36","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.4049\/jimmunol.0900127","article-title":"Alpha 2-macroglobulin capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity","volume":"182","author":"Raymond","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.healun.2016.08.022_bib37","doi-asserted-by":"crossref","first-page":"260346","DOI":"10.1155\/2013\/260346","article-title":"A systematic review to investigate whether Angiotensin-(1\u20137) is a promising therapeutic target in human heart failure","volume":"2013","author":"Lee","year":"2013","journal-title":"Int J Pept"},{"key":"10.1016\/j.healun.2016.08.022_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.biocel.2008.02.022","article-title":"Prolylcarboxypeptidase: a cardioprotective enzyme","volume":"41","author":"Mallela","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.healun.2016.08.022_bib39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2016.08.022_bib40","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1409077","article-title":"Neprilysin inhibition for heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2016.08.022_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12916-015-0272-0","article-title":"Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice","volume":"13","author":"Filippatos","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.healun.2016.08.022_bib42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.healun.2014.04.019","article-title":"A contemporary review of adult heart transplantation: 2012 to 2013","volume":"33","author":"DePasquale","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.08.022_bib43","doi-asserted-by":"crossref","first-page":"e002679","DOI":"10.1161\/CIRCHEARTFAILURE.115.002679","article-title":"Matching the Market for Heart Transplantation","volume":"9","author":"Hsich","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.healun.2016.08.022_bib44","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/HYPERTENSIONAHA.112.198622","article-title":"Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2","volume":"60","author":"Ye","year":"2012","journal-title":"Hypertension"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249816303102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249816303102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:33:26Z","timestamp":1760949206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249816303102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1053249816303102"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2016.08.022","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2016.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}